Endocrine Abstracts

Tocilizumab is an interleukin-6 receptor antagonist used in the treatment of rheumatoid arthritis (RA). It is known to induce remission and inhibit radiographic progression in RA. Tocilizumab may be administered either intravenously or subcutaneously. Its effect on lipid levels and the cardiovascular risk has not been fully investigated. The aim was to study the effect of tocilizumab administered either iv or sc on disease activity, lipid levels and cardiovascular risk in RA p...

Nonalcoholic fatty liver disease has an increased worldwide prevalence due to obesity and the use of various drugs affecting the liver. The pathogenesis of nonalcoholic fatty liver disease is presently not completely defined. In addition, there is a paucity of agents for its treatment. Choline deficiency has been shown to induce nonalcoholic liver disease. Systemic autoimmune rheumatic diseases require chronic systemic treatment with various agents, which may affect liver func...